We combine deep chemical biology and cancer pharmacology know-how with sophisticated structure-based drug discovery capabilities and astute precision medicine approaches to develop novel targeted therapies.
We are developing novel targeted therapies to inhibit elusive frontier oncology targets within notorious growth and survival pathways, with a particular emphasis on the RAS and mTOR signaling pathways.
We are pursuing both combination and monotherapy precision medicine development strategies for our programs to allow us to target specific oncogenic mutations and combat adaptive resistance.
